Advanced search
Publication Cover
Journal of Chemotherapy Volume 25, 2013 - Issue 1
Submit an article Journal homepage
655
Views
7
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

Brian T Tsuji Laboratory for Antimicrobial PharmacodynamicsSchool of Pharmacy and Pharmaceutical Sciences;The New York State Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, State University of New York, NY, USACorrespondence[email protected]
,
Yoriko Harigaya Laboratory for Antimicrobial PharmacodynamicsSchool of Pharmacy and Pharmaceutical Sciences; (Presently) Food and Drug AdministrationCenter for Drug Evaluation and Research, Silver Spring, MD, USA
,
Alan J Lesse School of Medicine and Biomedical SciencesUniversity at Buffalo, State University of New York, NY, USA
,
Alan Forrest Laboratory for Antimicrobial PharmacodynamicsSchool of Pharmacy and Pharmaceutical Sciences
&
Dung Ngo Laboratory for Antimicrobial PharmacodynamicsSchool of Pharmacy and Pharmaceutical Sciences
Pages 32-35 | Published online: 12 Nov 2013

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Thomas Hunt, Nachum Kaplan & Barry Hafkin. (2016) Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects. Journal of Chemotherapy 28:3, pages 164-171.
Read now

Articles from other publishers (6)

Sandra Eltschkner, Josef Kehrein, Thien Anh Le, Shabnam Davoodi, Benjamin Merget, Sneha Basak, Jonas D. Weinrich, Johannes Schiebel, Peter J. Tonge, Bernd Engels, Christoph Sotriffer & Caroline Kisker. (2021) A Long Residence Time Enoyl-Reductase Inhibitor Explores an Extended Binding Region with Isoenzyme-Dependent Tautomer Adaptation and Differential Substrate-Binding Loop Closure. ACS Infectious Diseases 7:4, pages 746-758.
Crossref
Mark S Butler, Mark AT Blaskovich & Matthew A Cooper. (2016) Antibiotics in the clinical pipeline at the end of 2015. The Journal of Antibiotics 70:1, pages 3-24.
Crossref
Cheryl A. Jordan, Braddock A. Sandoval, Mkrtich V. Serobyan, Damian H. Gilling, Michael P. Groziak, H. Howard Xu & Jessica L. Vey. (2015) Crystallographic insights into the structure–activity relationships of diazaborine enoyl-ACP reductase inhibitors. Acta Crystallographica Section F Structural Biology Communications 71:12, pages 1521-1530.
Crossref
Barry Hafkin, Nachum Kaplan & Thomas L Hunt. (2015) Safety, tolerability and pharmacokinetics of AFN–1252 administered as immediate release tablets in healthy subjects. Future Microbiology 10:11, pages 1805-1813.
Crossref
Krishnamurthy Narasimha Rao, Anirudha Lakshminarasimhan, Sarah Joseph, Swathi U. Lekshmi, Ming‐Seong Lau, Mohammed Takhi, Kandepu Sreenivas, Sheila Nathan, Rohana Yusof, Noorsaadah Abd. Rahman, Murali Ramachandra, Thomas Antony & Hosahalli Subramanya. (2015) AFN ‐1252 is a potent inhibitor of enoyl‐ ACP reductase from B urkholderia pseudomallei —Crystal structure, mode of action, and biological activity . Protein Science 24:5, pages 832-840.
Crossref
Hui Wang, Yang Lu, Li Liu, Sung Won Kim, Jacob M. Hooker, Joanna S. Fowler & Peter J. Tonge. (2014) Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus. European Journal of Medicinal Chemistry 88, pages 66-73.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.